Pharmacological activation of REV-ERBα by SR9009 attenuated hepatic steatosis, insulin resistance, inflammation, and fibrosis in mice with intestinal barrier dysfunction-related disorders and NASH [233]. Here, NR1D1 is linked to fatty liver disease.